Drugs & therapy perspectives文章索引

Outcome measures in pediatric polypharmacy research: a scoping review [0.03%] 儿科多药治疗研究的结局指标：系统综述

Negar Golchin,Hannah Johnson,Paul M Bakaki et al. Negar Golchin et al.

Introduction: Various methods have been used to interpret the reports of pediatric polypharmacy across the literature. This is the first scoping review that explores outcome measures in pediatric polypharmacy research. ...

Drugs & therapy perspectives : for rational drug selection and use. 2019 Sep;35(9):447-458. DOI:10.1007/s40267-019-00650-8 2019

Assessing the impact of structured education on the knowledge of hospital pharmacists about adverse drug reactions and reporting methods in Saudi Arabia: an open-label randomised controlled trial [0.03%] 评估结构化教育对沙特阿拉伯医院药剂师关于药物不良反应知识及上报方法的影响：一项开放标签随机对照试验

Ejaz Cheema,Abdulmohsin Abdulaziz Almualem,Abdulmohsen Talal Basudan et al. Ejaz Cheema et al.

Background: Pharmacists have limited knowledge about adverse drug reactions (ADRs) in Saudi Arabia. Objective: The aim of this study wa...

Drugs & therapy perspectives : for rational drug selection and use. 2019;35(6):296-300. DOI:10.1007/s40267-019-00621-z 2019

Management of SARS relies on supportive measures and preventing the spread of infection [0.03%] SARS的管理依赖支持性措施和防止感染扩散

Drugs & therapy perspectives : for rational drug selection and use. 2006;22(3):16-19. DOI:10.2165/00042310-200622030-00005 2006

Is Pakistan prepared to tackle the coronavirus epidemic? [0.03%] 巴基斯坦准备好应对新型冠状病毒疫情了吗？

Muhammad Saqlain,Muhammad Muddasir Munir,Ali Ahmed et al. Muhammad Saqlain et al.

Drugs & therapy perspectives : for rational drug selection and use. 2020;36(5):213-214. DOI:10.1007/s40267-020-00721-1 2020

Coronavirus outbreaks: prevention and management recommendations [0.03%] 新型冠状病毒疫情爆发：预防与管理建议

Zakir Khan,Khayal Muhammad,Ali Ahmed et al. Zakir Khan et al.

Drugs & therapy perspectives : for rational drug selection and use. 2020;36(5):215-217. DOI:10.1007/s40267-020-00717-x 2020

Correction to: Afatinib in advanced NSCLC: a profile of its use [0.03%] Correction to: 阿法替尼在晚期非小细胞肺癌中的应用概况

Emma D Deeks,Gillian M Keating Emma D Deeks

[This corrects the article DOI: 10.1007/s40267-018-0482-6.].

Published Erratum Drugs & therapy perspectives : for rational drug selection and use. 2018;34(4):196. DOI:10.1007/s40267-018-0490-6 2018

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use [0.03%] 奥希替尼作为晚期NSCLC的一线治疗药物：其使用的概况及对修正意见的回应

Lesley J Scott Lesley J Scott

[This corrects the article DOI: 10.1007/s40267-018-0536-9.].

Published Erratum Drugs & therapy perspectives : for rational drug selection and use. 2019;35(1):50. DOI:10.1007/s40267-018-0594-z 2019

Correction to: Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use [0.03%] macrogol(聚乙二醇)4000非电解质制剂在慢性便秘对症治疗中的应用概况校更

Katherine A Lyseng-Williamson Katherine A Lyseng-Williamson

[This corrects the article DOI: 10.1007/s40267-018-0532-0.].

Published Erratum Drugs & therapy perspectives : for rational drug selection and use. 2019;35(1):49. DOI:10.1007/s40267-018-0588-x 2019

Correction to: Anakinra in Still's disease: a profile of its use [0.03%] still病中anakinra使用的概况及对它的评论补充

Katherine A Lyseng-Williamson Katherine A Lyseng-Williamson

[This corrects the article DOI: 10.1007/s40267-018-0572-5.].

Published Erratum Drugs & therapy perspectives : for rational drug selection and use. 2019;35(1):46. DOI:10.1007/s40267-018-0581-4 2019

Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use [0.03%] 对特发性肺纤维化中吡非尼酮片的使用概况一文的更正通知

Katherine A Lyseng-Williamson Katherine A Lyseng-Williamson

[This corrects the article DOI: 10.1007/s40267-017-0459-x.].

Published Erratum Drugs & therapy perspectives : for rational drug selection and use. 2018;34(8):404. DOI:10.1007/s40267-018-0534-y 2018